Partner 1- At the University of Geneva, the Genomic Research and Bacteriology Laboratory (GRBL) successfully developed an assay for the routine detection of MRSA. The laboratory will be the DNA provider. Their facilities will also allow the testing of diagnostic plateforms during the project.

Partner 2 - Spinomix SA is a start-up company developing automated systems for diagnostic applications using magnetic nanoparticles in a microfluidic environment. They will integrate the different steps of the diagnostic process to yield an assay on a single miniature plateform.

Partner 4 - At the Albert-Ludwigs Universität of Freiburg, IMTEK is a leading academic research department specialized in the development of micro- fluidic platforms for biological applications. They will develop the microfluidic chip, in particular the integration of antibody-based, nucleic acid-based and detection steps.

Partner 5 - Ademtech is a leader in manufacturing of magnetic nanoparticles with specific features such as high homogeneity and iron content. Their task is to develop specific magnetic nanoparticles to fit the requirements of the detection plateform.

Partner 6 - SCIPROM is a young Swiss company that supports researchers in European and National projects, networks, and research consortia. SCIPROM helps with or takes over project construction, submission, negotiation, execution and management.

Partner 3 - TATAA Biocenter is a leading center in real-time PCR in Europe that develops unique approaches to determine gene expression levels and ratios in complex biological samples. Their role is the project is to develop multi gene amplification, hybridization and detection in a microfluidic chamber.